Abstract 31P
Background
HRAS mutations have been found in 6% of HNSCCs. T cell exhaustion, defined as dysfunctional T cells stimulated by continuous antigen exposure. To guide immunotherapeutic approaches, we sought to assess the immune landscape of HRAS-mutant tumors by investigating the subpopulations of pre-exhausted and exhausted T cells.
Methods
We found 10 cases of HRAS mutant tumors and 39 cases of HRAS wild-type (WT) tumors. We sought to characterize exhausted CD8+ T cell subpopulations by measuring the expression of T-cell Factor-1 (TCF-1) and Programmed Cell Death-1 (PD-1) in the tumor's center (C) and periphery (P). Multiplex immunohistochemistry (IHC) was performed in FFPE tissue sections using three primary antibodies (PD1-CD8-TCF1/7), followed by analysis of a manually trained algorithm in Qupath software.
Results
HRAS mutant tumors present numerically higher numbers of total immune cells both in the C and the P than HRAS-WT tumors, that reached statistical significance only in the P (5123.17/mm2vs. 3527.93/mm2, p=0.002). In addition, the density of CD8+ T Cells was increased in both the C (694.10/mm2 vs. 356.02/mm2) and the P (851.10/mm2 vs. 333.30/mm2) in HRAS mutant tumors. Importantly, the percentage of pre-exhausted CD8 (+) T Cells was elevated in the P of HRAS mutant tumors (384.67/mm2vs. 51.18/mm2, p=0.040), indicating a possible association of response to ICB, since pre-exhausted T cells mediate the proliferative response to immunotherapy. On the contrary, exhausted T cells, defined as PD-1(+)TCF-1 (-) were more abundant in the C of HRAS mutant tumors compared to WT (13.77% vs. 2.67% of total CD8+ cells, p=0.022). Moreover, increased area occupied by CD11c+ dendritic cells and numbers of CD8+ T cells were found in regional lymph nodes from HRAS mutant patients (79.25% vs 38.80%, p=0.036 and 10160.43 vs 4438.28/mm2, p=0.036, respectively), consistent with data showing that maintenance of TCF1 by intratumoral T cells requires continuous migration from draining lymph nodes.
Conclusions
Pre-exhausted PD-1(+)TCF-1(+) T cells are significantly increased at the periphery of HRAS mutant tumors, suggesting a potential sensitivity of these tumors to ICB.
Legal entity responsible for the study
The authors.
Funding
Kura Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
157TiP - Krascendo-170 Lung: a phase Ib/II study of divarasib + pembrolizumab _ platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ferdinandos Skoulidis
Session: Poster Display
159TiP - Two Phase 1 Studies Assessing the Safety and Efficacy of the Small Molecule Oral PD-L1 Inhibitor INCB099280 in Combination with Adagrasib (INCB 99280-204 [Study 204]) or Ipilimumab (INCB 99280-205 [Study 205]) in Adults with Advanced Solid Tumors
Presenter: David Berz
Session: Poster Display
160TiP - Safety and Antitumor Activity of GEN1042 in Combination with Pembrolizumab _ Chemotherapy in Solid Tumors: Phase 2b Dose-Expansion Trial in Progress
Presenter: Ignacio Melero
Session: Poster Display
164P - Disentangling the Joint and Distinct Immunomodulation and Vulnerability Between KEAP1/NFE2L2 and SMARCA4 Alterations in Lung Adenocarcinoma
Presenter: Anlin Li
Session: Poster Display
165P - Immunosuppressive F13A1+ Mo/M_ in the tumor microenvironment as a hallmark for multiple primary lung cancers
Presenter: Jiahao Qu
Session: Poster Display
166P - Three-dimensional (3D) Innervation of Mouse Lungs and Airways in a Lung Metastatic Tumor Model
Presenter: Yan Zhou
Session: Poster Display
167P - Lurbinectedin, a DNA minor groove inhibitor launches a multimodal immune response through activation of the cytosolic DNA-Sensing cGAS-STING pathway.
Presenter: Triparna Sen
Session: Poster Display
168P - Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC
Presenter: CATERINA DE ROSA
Session: Poster Display
169P - High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer
Presenter: Angelica Rigutto
Session: Poster Display